| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2012-09-10 | MedImmune (USA), the global biologics arm of AstraZeneca (UK), WuXi AppTec (China) | MEDI5117 | autoimmune diseases, inflammatory diseases | joint venture |
Autoimmune diseases - Inflammatory diseases - Immunological diseases | Joint-venture agreement |
| 2012-09-10 | ALK Abello (Denmark) Merck MSD France (USA - France) | Grazax® (immunotherapy tablet) | grass pollen allergy | co-promotion |
Respiratory diseases - Allergic diseases | Co-promotion agreement |
| 2012-09-10 | Oryzon (Spain) Cancer Research UK’s Paterson Institute for Cancer Research (UK) | LSD1 inhibitors | acute leukemia | R&D |
Cancer - Oncology | R&D agreement |
| 2012-09-07 | Lundbeck (Denmark) Biotie Therapies (Finland) | Selincro™ (nalmefene) | alcohol dependence | commercialisation |
Commercialisation agreement | |
| 2012-09-07 | GSK (UK) The Cambridge University (UK) | Alpha-1 antitrypsin (A1AT) deficiency | R&D | Genetic diseases - Liver diseases | ||
| 2012-09-06 | Astex Pharmaceuticals (USA) Cancer Research Technology (UK) The Institute of Cancer Research (UK) | drug candidates targeting an undisclosed epigenetic target in a blood cancer | undisclosed blood cancer with high unmet medical need | R&D |
Cancer - Oncology | R&D agreement |
| 2012-09-06 | Boehringer Ingelheim (Germany) ETH Zurich (Switzerland) | diabetes, obesity | R&D |
Metabolic diseases | R&D agreement | |
| 2012-09-05 | Medivir (Sweden) Novadex Pharmaceuticals (Sweden) | preclinical antiviral programs including novel nucleotide polymerase inhibitors | hepatitis C | acquisition of preclinical research stage assets |
Infectious diseases | Pipeline acquisition |
| 2012-09-04 | Vivalis (France) undisclosed major non-governmental vaccine research institute | EB66® cell line | Collaboration agreement | |||
| 2012-09-04 | BioLineRx (Israel) Biokine Therapeutics (Israel) | BL-8040 | acute myeloid leukemia and other types of hematological cancers | development |
Cancer - Oncology | Development agreement |
| 2012-09-03 | Biofocus, a Galapagos Company (UK - Belgium) - Ono Pharmaceutical (Japan) | novel drugs in the field of CNS disorders | CNS diseases | R&D |
CNS diseases | R&D agreement |
| 2012-08-31 | NeuroSearch (Denmark) Anonia (Denmark) Janssen Pharmaceutica - J&J (USA) | NSD-788, NSD-721 and preclinical projects and early research projects | CNS diseases | R&D |
CNS diseases | R&D agreement |
| 2012-08-29 | Angel Biotechnology (UK) Argentis Pharmaceuticals (USA) | ARG201 | systemic sclerosis | manufacturing |
Autoimmune diseases | Production agreement |
| 2012-08-28 | Vivalis (France) BioFactura (USA) | EB66® cell line for the development of a novel human vaccine platform and candidate vaccine | undisclosed | licensing |
Licensing agreement | |
| 2012-08-22 | Silence Therapeutics (UK) MiReven Pty (Australia) | miR-7 mimetic | various cancers known to be controlled by the EGF receptor signaling pathway | R&D |
Cancer - Oncology | Development agreement |
| 2012-08-21 | Pluristem Therapeutics (Israel) Berlin-Brandenburg Center for Regenerative Therapy - Charite University Medicine (Germany) | R&D |
Regenerative medicine - Muscular diseases | R&D agreement | ||
| 2012-08-21 | VolitionRX (Singapore) Belgian Volition (Belgium) CHU UCL Mont-Godinne Hospital (Belgium) | non-invasive blood tests for early detection and prognosis of colorectal cancer | colorectal cancer | clinical research |
Cancer - Oncology | Clinical research agreement |
| 2012-08-20 | Alligator Bioscience (Sweden) undisclosed Swedish biotech company | novel medical products | undisclosed | R&D |
undisclosed | R&D agreement |
| 2012-08-16 | Algeta (Norway) Cobra Biologics (UK -Sweden) | undisclosed monoclonal antibody, which is highly selective for a validated cell surface target on hematological cancer cells, linked to the alpha-particle emitter thorium-227 (Th-227) | hematological cancers | R&D |
Cancer - Oncology | Production agreement |
| 2012-08-15 | Cancer Research Technology (CRT) (UK) Cancer Therapeutics CRC (Australia) | pre-clinical focal adhesion kinase (FAK) inhibitor programmes including CTx-0294945 and CTx-0294886 | triple-negative breast cancer, merlin-negative mesothelioma, solid tumors | licensing |
Cancer - Oncology | Licensing agreement |
